<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37099136</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.</ArticleTitle><Pagination><StartPage>405</StartPage><EndPage>413</EndPage><MedlinePgn>405-413</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad182</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mortality related to hepatitis C virus (HCV) infection is a key indicator for elimination. We assessed the impact of HCV infection and treatment on mortality in the country of Georgia during 2015-2020.</AbstractText><AbstractText Label="METHODS">We conducted a population-based cohort study using data from Georgia's national HCV Elimination Program and death registry. We calculated all-cause mortality rates in 6 cohorts: (1) Negative for anti-HCV; (2) anti-HCV positive, unknown viremia status; (3) current HCV infection and untreated; (4) discontinued treatment; (5) completed treatment, no sustained virologic response (SVR) assessment; (6) completed treatment and achieved SVR. Cox proportional hazards models were used to calculate adjusted hazards ratios and confidence intervals. We calculated the cause-specific mortality rates attributable to liver-related causes.</AbstractText><AbstractText Label="RESULTS">After a median follow-up of 743 days, 100 371 (5.7%) of 1 764 324 study participants died. The highest mortality rate was observed among HCV infected patients who discontinued treatment (10.62 deaths per 100 PY, 95% confidence interval [CI]: 9.65, 11.68), and untreated group (10.33 deaths per 100 PY, 95% CI: 9.96, 10.71). In adjusted Cox proportional hazards model, the untreated group had almost 6-times higher hazard of death compared to treated groups with or without documented SVR (adjusted hazard ratio [aHR] = 5.56, 95% CI: 4.89, 6.31). Those who achieved SVR had consistently lower liver-related mortality compared to cohorts with current or past exposure to HCV.</AbstractText><AbstractText Label="CONCLUSIONS">This large population-based cohort study demonstrated the marked beneficial association between hepatitis C treatment and mortality. The high mortality rates observed among HCV infected and untreated persons highlights the need to prioritize linkage to care and treatment to achieve elimination goals.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gvinjilia</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Eastern Europe and Central Asia Regional Office, Centers for Disease Control and Prevention, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baliashvili</LastName><ForeName>Davit</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8390-3325</Identifier><AffiliationInfo><Affiliation>The Task Force for Global Health, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadaker</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Averhoff</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandelaki</LastName><ForeName>Levan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kereselidze</LastName><ForeName>Maia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsertsvadze</LastName><ForeName>Tengiz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinic "Hepa," Tbilisi, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chkhartishvili</LastName><ForeName>Nikoloz</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butsashvili</LastName><ForeName>Maia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Research Union and Clinic NeoLab, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metreveli</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinic "Mrcheveli," Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamkrelidze</LastName><ForeName>Amiran</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Paige A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005845" MajorTopicYN="N" Type="Geographic">Georgia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="Y">Hepatitis C</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="Y">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Potential conflicts of interest. D. B. reports consulting fees from World Health Organization (served as a consultant for piloting the tools for validation of viral hepatitis elimination). F. A. reports stock or stock options with Abbott. M. B. reports the following grants or contracts unrelated to this work: Integrated bio-behavioral surveillance survey among persons who inject drugs (PWID) in Georgia, NCDC Georgia, and missing sustained virologic response (SVR) data among patients enrolled in HCV elimination program&#x2014;barriers to assessment including coronavirus disease 2019 (COVID-19) pandemic's effects, Rustaveli Foundation. M. B. also reports payment or honoraria for Long COVID, training course for primary care physicians, Pfizer. N. C. reports the following grants or contracts unrelated to this work and paid to institution: An International Observational Study of Outpatients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, supported by National Institutes of Health (NIH); An International Observational Study of Outpatients with SARS-CoV-2 Infection, supported by NIH; An International Observational Study of Outpatients with SARS-CoV-2 Infection, supported by NIH; and An International Observational Study of Outpatients with SARS-CoV-2 Infection, supported by NIH. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37099136</ArticleId><ArticleId IdType="mid">NIHMS1917443</ArticleId><ArticleId IdType="pmc">PMC10527899</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad182</ArticleId><ArticleId IdType="pii">7143199</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Geneva; 2021.</Citation></Reference><Reference><Citation>World Health Organization. Global hepatitis report 2017. Geneva, 2017. April 2017.</Citation></Reference><Reference><Citation>World Health Organization. Global Health Sector Strategy on viral hepatitis 2016&#x2013;2021. Geneva, 2016.</Citation></Reference><Reference><Citation>Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34384530</ArticleId></ArticleIdList></Reference><Reference><Citation>Das D, Pandya M. Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis C therapy. Mini Rev Med Chem 2018; 18:584&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28901852</ArticleId></ArticleIdList></Reference><Reference><Citation>Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opin Drug Saf 2016; 15:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">27875916</ArticleId></ArticleIdList></Reference><Reference><Citation>Spengler U Direct antiviral agents (DAAs)&#x2014;a new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2018; 183:118&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29024739</ArticleId></ArticleIdList></Reference><Reference><Citation>Innes H, McDonald S, Hayes P, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 2017; 66: 19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">27545496</ArticleId></ArticleIdList></Reference><Reference><Citation>Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 68:827&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29377196</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393:1453&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30765123</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018; 17:377&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433385</ArticleId><ArticleId IdType="pubmed">30923667</ArticleId></ArticleIdList></Reference><Reference><Citation>Baliashvili D, Averhoff F, Kasradze A, et al. Risk factors and genotype distribution of hepatitis C virus in Georgia: a nationwide population-based survey. PLoS One 2022; 17:e0262935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782338</ArticleId><ArticleId IdType="pubmed">35061841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan LM, Kasradze A, Salyer SJ, et al. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination. BMC Public Health 2019; 19-(Suppl 3):480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696670</ArticleId><ArticleId IdType="pubmed">32326913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide hepatitis C elimination program&#x2013;Georgia, April 2015. MMWR Morb Mortal Wkly Rep 2015; 64:753&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584859</ArticleId><ArticleId IdType="pubmed">26203628</ArticleId></ArticleIdList></Reference><Reference><Citation>Gvinjilia L, Nasrullah M, Sergeenko D, et al. National progress toward hepatitis C elimination&#x2013;Georgia, 2015&#x2013;2016. MMWR Morb Mortal Wkly Rep 2016; 65: 1132&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27764081</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrullah M, Sergeenko D, Gvinjilia L, et al. The role of screening and treatment in national progress toward hepatitis C elimination&#x2013;Georgia, 2015&#x2013;2016. MMWR Morb Mortal Wkly Rep 2017; 66:773&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657814</ArticleId><ArticleId IdType="pubmed">28749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, et al. Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015&#x2013;March 2018. Clin Infect Dis 2020; 71:1263&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484896</ArticleId><ArticleId IdType="pubmed">31563938</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgia Hepatitis Elimination Program Progress Report, 2020&#x2013;2021, 2022.</Citation></Reference><Reference><Citation>Averhoff F, Shadaker S, Gamkrelidze A, et al. Progress and challenges in a pioneering hepatitis C elimination program in the country of Georgia, 2015&#x2013;2018. J Hepatol 2020; 72:680&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418146</ArticleId><ArticleId IdType="pubmed">31811882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda JA, Thomas DL, Astemborski J, et al. Impact of hepatitis C treatment up-take on cirrhosis and mortality in persons who inject drugs: a longitudinal, community-based cohort study. Ann Intern Med 2022; 175:1083&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706936</ArticleId><ArticleId IdType="pubmed">35816712</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelsameea E, Alsebaey A, Abdel-Samiee M, Abdel-Razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Rev Anti-infect Ther 2021; 19:1053&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307880</ArticleId></ArticleIdList></Reference><Reference><Citation>Witth&#xf6;ft T, M&#xf6;ller B, Wiedmann KH, et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German open safety trial. J Viral Hepatitis 2007; 14:788&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156112</ArticleId><ArticleId IdType="pubmed">17927615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridruejo E, Adrover R, Cocozzella D, Fernandez N, Reggiardo MV. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-interferon - ribavirin in daily practice. Ann Hepatol 2010; 9:46&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308722</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-H, Liu C-J, Su T-H, et al. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018; 13:e0209299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303025</ArticleId><ArticleId IdType="pubmed">30576344</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggisch P, Wursthorn K, Stoehr A, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One 2019; 14:e0214795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448908</ArticleId><ArticleId IdType="pubmed">30946776</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022; 76:302&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">34592366</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro F Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021; 74:952&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">33276027</ArticleId></ArticleIdList></Reference><Reference><Citation>Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection. Ann Internal Med 2017; 166:637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486987</ArticleId><ArticleId IdType="pubmed">28319996</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Disease Control and Public Health of Georgia. Statistical Yearbook 2018, 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>